However, recent reports have described the incidence of concomitant EGFR mutations and ALK rearrangement at a rate of 0.45–1.6% in patients with NSCLC, accounting for 3.9–13.6% of EGFR-mutant and 15.4–18.8% of ALK-rearranged patients (17, 34, 36, 109). Here, EGFR is linked to non-small cell lung carcinoma.